帕利哌酮缓释片和奥氮平片治疗儿童青少年精神分裂症的效果和安全性比较

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (499 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy and safety of Paliperidone Extended-Release Tablets and Olanzapine Tablets in the treatment of schizophrenia in children and adolescents.Methods A total of 100 patients with schizophrenia who were admitted to our hospital from April 2013 to April 2016 were selected as subjects,and randomly divided into the Paliperidone Extended-Release Tablets group (group P,n=50) and Olanzapine Tablets group (group A,n=48).Both groups were treated for 12 weeks.PANSS scores were compared between the two groups before treatment and 1,2,4,6,8,10 and 12 weeks after treatment.The incidence of adverse reactions were also compared between the two groups.Results The patients in the group P was effective earlier than that in group A,and the difference was statistically significant (P<0.05).When medication was extended to 12 weeks after treatment,the efficacy of the two groups was compared,and difference was not statistically significant (P>0.05).The incidence of narcolepsy,abnormal liver function,abnormal blood lipid and weight gain were lower in group P than those in group A,the incidence of akathisia was higher than group A,and the differences were statistically significant (P<0.05).Conclusion Paliperidone Extended-Release Tablets and Olanzapine Tablets has similar efficacy in the treatment of schizophrenia in children and adolescents,but Paliperidone Extended-Release Tablets has less side effects than Olanzapine Tablets,and it works faster.

Key words： Paliperidone Extended-Release Tablets Olanzapine Tablets Children and adolescents Schizophrenia

Received: 16 May 2017

PACS:

R749.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Duo-cong
	CHEN Hai-feng

Cite this article:

LI Duo-cong,CHEN Hai-feng. Comparison of efficacy and safety of Paliperidone Extended-Release Tablets and Olanzapine Tablets in the treatment of schizophrenia in children and adolescents[J]. 中国当代医药, 2017, 24(24): 75-77.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I24/75

[1]	陶国泰,郑毅,宋维村.儿童少年精神医学[M].南京：江苏科学技术出版社,2008：291.
[2]	李淑芬,李素水,王克强,等.国外儿童青少年精神分裂症治疗研究进展[J].中国健康心理学杂志,2011,19（5）：626-628.
[3]	刘叶红,万爱华,王丽娜,等.门诊与住院精神分裂症患者首选药物调查[J].中国心理学杂志,2012,20（2）：170-171.
[4]	Gareri P,Segura-García C,Manfredi VGL, et al .Use of atypical antipsychotics in the elderly：a clinical review[J]. Clin Interv Aging,2014,9：1363.
[5]	Komossa K,Rummel Kluge C,Schwarz S, et al. Risperdone versus other atypical antipsychotics for schizophrenia[J].cochrane Database Syst Rev,2011,8（1）：968-970.
[6]	何艳玲,张明圆.阳性和阴性症状量表中国常模和因子分析[J].中国临床心理学杂志,2000,8（2）：65-69.
[7]	Reading R.Mental health of young people：a global public-health challenge[J].Lancet,2007,369（9569）：1302.
[8]	郝伟,于欣.精神病学（第7版）[M].北京：人民卫生出版社,2013：24.
[9]	Pani L,Marchese G.Expected clinical benefits of paliperidone extended-relsasd formulation when compared with risperidone immediate-release expert opin[J].Drug Deliv,2009,6（3）：319-331.
[10]	Fowler JA,Bettnger TL,Argo TR.Paliperidone extended-release tab lets for the acute and maintenance of schizophrenia[J].Clin Ther,2008,30（2）：231-248.
[11]	Gray JA,Roth BL.The pipeline and future of drug development in schizophrenia[J].Mol Psychiatry,2007,12（10）：904-922.
[12]	Turgay A,Binder C,Snyder R, et al .Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs[J].Pediatrics,2002,110（3）：e34.
[13]	江开达.精神药理学（第2版）[M].北京：人民卫生出版社,2011：332-333.
[14]	高明,林涌超.帕利哌酮与奥氮平治疗精神分裂的对照研究[J].海峡药学,2016,28（9）：93-95.
[15]	韩攸村,黄同旭.帕利派酮缓释片与奥氮平治疗精神分裂症疗效及对认知功能影响对照研究[J].精神医学杂志,2017,30（1）：53-55.
[16]	李四冬,阳前军,熊华朝,等.帕利哌酮与奥氮平对精神分裂症首发女性患者疗效及代谢、体质量的影响[J].国际精神病学杂志,2015,42（3）：3-6.
[17]	司天梅,黄继忠,李小白,等.帕利哌酮缓释片临床用药指导意见（第二版）[J].中国新药杂志,2016,25（9）：1029-1030.
[18]	赵靖平,施慎逊.中国精神分裂症防治指南（第2版）[M].中华医学电子音像出版社,2015：78.